Edrophonium chloride
[CAS# 116-38-1]

Identification

• Classification: API >> Anesthetic agents >> Skeletal muscle relaxant
• Name: Edrophonium chloride
• Synonyms: N-Ethyl-3-hydroxy-N,N-dimethylanilinium chloride
• Molecular Formula: C₁₀H₁₆NO.Cl
• Molecular Weight: 201.69
• CAS Registry Number: 116-38-1
• EC Number: 204-138-4
• SMILES: CC[N+](C)(C)C1=CC(=CC=C1)O.[Cl-]

Properties

• Solubility: 31 mg/mL (DMSO)

Safety Data

• Hazard Symbols: GHS07 Warning
• Risk Statements: H302-H315-H319-H335
• Safety Statements: P261-P305+P351+P338

Discovery and Applications

Edrophonium chloride is a quaternary ammonium compound that has gained significant attention in the fields of pharmacology and medicine, particularly for its role as a short-acting reversible inhibitor of the enzyme acetylcholinesterase. This compound, also known by its trade name Tensilon, was first synthesized in the 1950s as part of efforts to develop medications for various neuromuscular disorders.

The discovery of edrophonium chloride was driven by the need to improve diagnostic tools for myasthenia gravis, an autoimmune disease characterized by weakness and rapid fatigue of voluntary muscles. Researchers identified that inhibiting acetylcholinesterase could enhance the availability of acetylcholine at neuromuscular junctions, leading to improved muscle contraction and function. This paved the way for the use of edrophonium chloride as a diagnostic agent in determining the presence of myasthenia gravis.

Edrophonium chloride works by binding to acetylcholinesterase, the enzyme responsible for breaking down acetylcholine in the synaptic cleft. By inhibiting this enzyme, edrophonium increases the concentration of acetylcholine, thereby enhancing neurotransmission and muscle strength in patients suffering from myasthenia gravis. Clinicians often administer edrophonium chloride during diagnostic tests to observe transient improvements in muscle strength, which supports the diagnosis of the condition.

In addition to its diagnostic applications, edrophonium chloride has been used therapeutically to treat myasthenic crises—episodes of severe muscle weakness that can occur in individuals with myasthenia gravis. Its rapid onset of action and short duration of effect make it an effective choice in emergency situations, allowing healthcare providers to quickly assess and manage symptoms.

Furthermore, edrophonium chloride has been investigated for its potential applications in other medical conditions. Research has explored its use in treating various types of poisoning, particularly those involving anticholinergic agents, by counteracting the effects of excessive acetylcholine breakdown. Additionally, it has been studied in the context of certain neurological disorders, where cholinergic dysfunction may play a role.

Despite its therapeutic benefits, edrophonium chloride is not without limitations. Its short half-life necessitates frequent dosing in clinical settings, which can be inconvenient for patients and healthcare providers alike. Moreover, the compound may cause side effects such as gastrointestinal disturbances, muscle cramps, and bradycardia, particularly when administered in high doses or to individuals with pre-existing conditions.

Safety considerations have also prompted ongoing research into alternative cholinesterase inhibitors that offer longer-lasting effects and improved safety profiles. Nevertheless, edrophonium chloride remains a valuable tool in the diagnosis and management of myasthenia gravis and continues to be used in clinical practice.

In summary, edrophonium chloride is a significant chemical compound in the realm of pharmacology, primarily recognized for its role as a diagnostic and therapeutic agent in myasthenia gravis. Its discovery and application highlight the importance of acetylcholinesterase inhibitors in enhancing neuromuscular transmission and improving patient outcomes. As research progresses, edrophonium chloride may continue to play a pivotal role in understanding and treating neuromuscular disorders.

References

2017. Evaluation of the Edrophonium Challenge Test for Cervical Dystonia. Internal medicine (Tokyo, Japan).
DOI: 10.2169/internalmedicine.8555-16

1994. Antagonism of Mivacurium-induced Neuromuscular Blockade in Humans: Edrophonium Dose Requirements at Threshold Train-of-Four Count of 4. Anesthesiology.
DOI: 10.1097/00000542-199412000-00014

1984. Clinical Pharmacology of Edrophonium in Infants and Children. Anesthesiology.
DOI: 10.1097/00000542-198410000-00011